Hoshino M, Takahashi M, Takai Y, Sim J
Second Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.
J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):356-63. doi: 10.1016/s0091-6749(99)70379-9.
Bronchial asthma is characterized by airway wall remodeling. Matrix metalloproteinases (MMPs) are members of a family of proteolytic enzymes that degrade the extracellular matrix and that restrain the effects of their tissue inhibitors (TIMPs). Treatment with inhaled corticosteroids may prevent airway remodeling in asthma. However, the effects of corticosteroid treatment on MMPs and TIMPs in asthma are unknown.
We examined the effects of inhaled beclomethasone dipropionate (BDP) on the expression of MMP-9 and TIMP-1 and subepithelial collagen deposition in bronchial biopsy specimens from 30 subjects with asthma.
Inhaled BDP, 800 microg daily, or placebo was administered for 6 months in a double-blind, parallel-group study, and bronchial biopsies were performed before and after treatment. Biopsy specimens were examined for extent of collagen type III in the subepithelial basement membrane by means of immunohistochemistry, and expression of both epithelial and submucosal MMP-9 and TIMP-1 was quantitated. Numbers of inflammatory cells were also determined.
We observed significant decreases in collagen type III deposition (P <.01) and the expression of submucosal MMP-9 (P <.01) and a significant increase in the expression of submucosal TIMP-1 (P <.05) in the BDP group. Significant correlations were found between the subepithelial collagen type III deposition and epithelial (r (s ) = 0.37, P <.05) and submucosal expression of MMP-9 (r (s ) = 0.47, P <.01). Additionally, the number of many inflammatory cells and myofibroblasts in airway mucosa were significantly decreased in the BDP group.
Our findings suggest that corticosteroid treatment of asthma can reduce subepithelial collagen deposition by downregulation of MMP-9 expression and upregulation of TIMP-1 expression.
支气管哮喘的特征是气道壁重塑。基质金属蛋白酶(MMPs)是一类蛋白水解酶家族成员,可降解细胞外基质并抑制其组织抑制剂(TIMPs)的作用。吸入糖皮质激素治疗可能预防哮喘中的气道重塑。然而,糖皮质激素治疗对哮喘中MMPs和TIMPs的影响尚不清楚。
我们研究了吸入丙酸倍氯米松(BDP)对30例哮喘患者支气管活检标本中MMP-9和TIMP-1表达以及上皮下胶原沉积的影响。
在一项双盲、平行组研究中,每日吸入800微克BDP或安慰剂,持续6个月,并在治疗前后进行支气管活检。通过免疫组织化学检查活检标本上皮下基底膜中III型胶原的程度,并对上皮和黏膜下MMP-9和TIMP-1的表达进行定量。还测定了炎症细胞数量。
我们观察到BDP组中III型胶原沉积显著减少(P<.01)、黏膜下MMP-9表达显著降低(P<.01)以及黏膜下TIMP-1表达显著增加(P<.05)。上皮下III型胶原沉积与上皮MMP-9表达(r(s)=0.37,P<.05)和黏膜下MMP-9表达(r(s)=0.47,P<.01)之间存在显著相关性。此外,BDP组气道黏膜中许多炎症细胞和成肌纤维细胞的数量显著减少。
我们的研究结果表明,哮喘的糖皮质激素治疗可通过下调MMP-9表达和上调TIMP-1表达来减少上皮下胶原沉积。